Véronique BEREZIAT

Dr. Véronique BEREZIAT

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
GBGuillaume Bidault
Guillaume Bidault
MGMarie Garcia
Marie Garcia
MVMarie-Christine Vantyghem
Marie-Christine Vantyghem
PDPierre-Henri Ducluzeau
Pierre-Henri Ducluzeau
RMRomain Morichon
Romain Morichon
VBVéronique BEREZIAT
Véronique BEREZIAT
Objective—: Some mutations in LMNA , encoding A-type lamins, are responsible for Dunnigan-type-familial partial lipodystrophy (FPLD2), with altered fat distribution and metabolism. The high prevalence of early and severe cardiovascular outcomes in these patients suggests that, in addition to metabolic risk factors, FPLD2-associated LMNA mutations could have a direct role on the vascular wall cells. Approach and Results—: We analyzed the cardiovascular phenotype of 19 FPLD2 patients aged >30 years with LMNA p.R482 heterozygous substitutions, and the effects of p.R482W-prelamin-A overexpression in human coronary artery endothelial cells. In 68% of FPLD2 patients, early atherosclerosis was attested by clinical cardiovascular events, occurring before the age of 45 in most cases. In transduced endothelial cells, exogenous wild-type-prelamin-A was correctly processed and localized, whereas p.R482W-prelamin-A accumulated abnormally at the nuclear envelope. Patients’ fibroblasts also showed a predominant nuclear envelope distribution with a decreased rate of prelamin-A maturation. Only p.R482W-prelamin-A induced endothelial dysfunction, with decreased production of NO, increased endothelial adhesion of peripheral blood mononuclear cells, and cellular senescence. p.R482W-prelamin-A also induced oxidative stress, DNA damages, and inflammation. These alterations were prevented by treatment of endothelial cells with pravastatin, which inhibits prelamin-A farnesylation, or with antioxidants. In addition, pravastatin allowed the correct relocalization of p.R482W-prelamin-A within the endothelial cell nucleus. These data suggest that farnesylated p.R482W-prelamin-A accumulation at the nuclear envelope is a toxic event, leading to cellular oxidative stress and endothelial dysfunction. Conclusions—: LMNA p.R482 mutations, responsible for FPLD2, exert a direct proatherogenic effect in endothelial cells, which could contribute to patients’ early atherosclerosis.

21 September 2021 in eLife
Verified
Journal Article
Open access
LPLaura Le Pelletier
Laura Le Pelletier
MMMatthieu Mantecon
Matthieu Mantecon
JGJennifer Gorwood
Jennifer Gorwood
MAMartine Auclair
Martine Auclair
RFRoberta Foresti
Roberta Foresti
VBVéronique BEREZIAT
Véronique BEREZIAT
Aging is associated with central fat redistribution and insulin resistance. To identify age-related adipose features, we evaluated the senescence and adipogenic potential of adipose-derived stromal cells (ASCs) from abdominal subcutaneous fat obtained from healthy normal-weight young (60 years). Increased cell passages of young-donor ASCs (in vitro aging) resulted in senescence but not oxidative stress. ASC-derived adipocytes presented impaired adipogenesis but no early mitochondrial dysfunction. Conversely, aged-donor ASCs at early passages displayed oxidative stress and mild senescence. ASC-derived adipocytes exhibited oxidative stress, and early mitochondrial dysfunction but adipogenesis was preserved. In vitro aging of aged-donor ASCs resulted in further increased senescence, mitochondrial dysfunction, oxidative stress, and severe adipocyte dysfunction. When in vitro aged young-donor ASCs were treated with metformin, no alteration was alleviated. Conversely, metformin treatment of aged-donor ASCs decreased oxidative stress and mitochondrial dysfunction resulting in decreased senescence. Metformin’s prevention of oxidative stress and of the resulting senescence improved the cells’ adipogenic capacity and insulin sensitivity. This effect was mediated by the activation of AMP-activated protein kinase as revealed by its specific inhibition and activation. Overall, aging ASC-derived adipocytes presented impaired adipogenesis and insulin sensitivity. Targeting stress-induced senescence of ASCs with metformin may improve age-related adipose tissue dysfunction.

13 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MZMaurice Zaoui
Maurice Zaoui
MMMehdi Morel
Mehdi Morel
NFNathalie Ferrand
Nathalie Ferrand
SFSoraya Fellahi
Soraya Fellahi
JBJean-Philippe Bastard
Jean-Philippe Bastard
Michèle SABBAHMichèle SABBAH
Michèle SABBAH
Breast adiposity is correlated with body mass index, menopausal status and mammary density. We here wish to establish how these factors influence the cross-talk between breast adipocytes and normal or malignant breast cells. Adipocyte-derived stem cells (ASCs) were obtained from healthy women and classified into six distinct groups based on body mass index, menopausal status and mammary density. The ASCs were induced to differentiate, and the influence of their conditioned media (ACM) was determined. Unexpectedly, there were no detectable differences in adipogenic differentiation and secretion between the six ASC groups, while their corresponding ACMs had no detectable influence on normal breast cells. In clear contrast, all ACMs profoundly influenced the proliferation, migration and invasiveness of malignant breast cells and increased the number of lipid droplets in their cytoplasm via increased expression of the fatty acid receptor CD36, thereby increasing fatty acid uptake. Importantly, inhibition of CD36 reduced lipid droplet accumulation and attenuated the migration and invasion of the breast cancer cells. These findings suggest that breast-associated adipocytes potentiate the invasiveness of breast cancer cells which, at least in part, is mediated by metabolic reprogramming via CD36-mediated fatty acid uptake.

1 November 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
VBVéronique BEREZIAT
Véronique BEREZIAT
PCPascale Cervera
Pascale Cervera
CDCaroline Le Dour
Caroline Le Dour
SDSylvie Dumont
Sylvie Dumont
MVMarie-Christine Vantyghem
Marie-Christine Vantyghem
CVCorinne Vigouroux
Corinne Vigouroux

12 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
GBGuillaume BIDAULT
Guillaume BIDAULT
MGMarie Garcia
Marie Garcia
JCJacqueline Capeau
Jacqueline Capeau
RMRomain Morichon
Romain Morichon
CVCorinne Vigouroux
Corinne Vigouroux
VBVéronique BEREZIAT
Véronique BEREZIAT
Hutchinson–Gilford progeria syndrome (HGPS) is a rare premature aging disorder notably characterized by precocious and deadly atherosclerosis. Almost 90% of HGPS patients carry a LMNA p.G608G splice variant that leads to the expression of a permanently farnesylated abnormal form of prelamin-A, referred to as progerin. Endothelial dysfunction is a key determinant of atherosclerosis, notably during aging. Previous studies have shown that progerin accumulates in HGPS patients’ endothelial cells but also during vascular physiological aging. However, whether progerin expression in human endothelial cells can recapitulate features of endothelial dysfunction is currently unknown. Herein, we evaluated the direct impact of exogenously expressed progerin and wild-type lamin-A on human endothelial cell function and senescence. Our data demonstrate that progerin, but not wild-type lamin-A, overexpression induces endothelial cell dysfunction, characterized by increased inflammation and oxidative stress together with persistent DNA damage, increased cell cycle arrest protein expression and cellular senescence. Inhibition of progerin prenylation using a pravastatin–zoledronate combination partly prevents these defects. Our data suggest a direct proatherogenic role of progerin in human endothelial cells, which could contribute to HGPS-associated early atherosclerosis and also potentially be involved in physiological endothelial aging participating to age-related cardiometabolic diseases.

1 May 2014 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
AGA.C. Guénantin
A.C. Guénantin
NBN. Briand
N. Briand
GBG. Bidault
G. Bidault
PAP. Afonso
P. Afonso
VBVéronique BEREZIAT
Véronique BEREZIAT
CVCorinne Vigouroux
Corinne Vigouroux